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Abstract
Background: A standardized definition of remission criteria in schizophrenia was proposed by the International
group of NC Andreasen in 2005 (low symptom threshold for the eight core Positive and Negative Syndrome Scale
(PANSS) symptoms for at least 6 consecutive months).
Methods: A cross-sectional study of remission rate, using a 6-month follow-up to assess symptomatic stability, was
conducted in two healthcare districts (first and second) of an outpatient psychiatric service in Moscow. The key
inclusion criteria were outpatients with an International Classification of Diseases, 10th edition (ICD-10) diagnosis of
schizophrenia or schizoaffective disorder. Remission was assessed using modern criteria (severity and time criteria),
PANSS and Global Assessment of Functioning (GAF). Patients who were stable but did not satisfied the symptomatic
criteria were included in a further 1-year observational study, with the first group (first district) receiving risperidone
(long-acting, injectable) (RLAI) and the second group (second district) continuing to receiving routine treatment.
Symptoms were assessed with PANSS, social functioning with the personal and social performance scale, compliance
with rating of medication influences scale, and extrapyramidal side effects with the Simpson-Angus scale.
Results: Only 64 (31.5%) of 203 outpatients met the criteria for symptomatic remission in the cross-sectional study,
but at the end of the 6-month follow-up period, 158 (77.8%) were stable (irrespective of remission status). Among
these only 53 (26.1%) patients fulfilled the remission criteria. The observational study had 42 stable patients in the
RLAI group and 35 in the routine treatment group: 19.0% in the RLAI group and 5.7% in the control group met
remission criteria after 12 months of therapy. Furthermore, reduction of PANSS total and subscale scores, as well as
improvement in social functioning, was more significant in the first group.
Conclusions: Only around one-quarter of our outpatient schizophrenic population met full remission criteria. Use
of RLAI gave a better remission rate than achieved in standard care with routine treatment. Criteria for remission
should take into account clinical course and functioning to support clinical care.
Introduction
Remission is commonly used in clinical practice to
describe the stable state of schizophrenic patients. Mod-
ern classifications such as the Diagnostic and Statistical
Manual of Mental Disorders, fourth edition (DSM-IV
[1]) and the International Classification of Diseases, 10th
edition (ICD-10 [2]) split remission into full and partial,
based on residual symptom occurrence, which gives a
lack of symptomatic and functional definitions of status,
and, consequently, an absence of specific defined thera-
peutic targets within the systems; therefore the diagnosis
of remission becomes highly subjective. Current clinical
psychiatry requires effective methodology to assess ther-
apeutic interventions, which, in turn, necessitate stan-
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The first international consensus-based criteria, pro-
posed by the Remission in Schizophrenia Working
Group [3], include two factors: a symptomatic (low
threshold of the eight core Positive and Negative Syn-
drome Scale (PANSS) symptoms [4]) criterion and a
time/duration (6 consecutive months) criterion. Selected
symptoms based on three dimensions (positive, negative,
disorganization), present distinct components for the dis-
order and incorporate five diagnostic criteria for schizo-
phrenia as specified in DSM-IV.
Validation of the international remission criteria was
made in naturalistic [5-7] and intervention [8,9] studies.
De Hert et al. [5] evaluated the maintenance of remission
over 1 year in a large naturalistic prospective study: 99
(29%) of the 341 patients met full remission criteria at the
end point, whereas 147 (43%) patients did not meet the
symptomatic criterion. Patients in remission had better
insight of their disorder and global and daily living func-
tioning. In a 12-week non-interventional naturalistic study
with quetiapine, 526 (59%) of 893 outpatients achieved
symptomatic remission [7]. Furthermore, analysis of
pooled data from 52-week, randomized, double-blind,
multicenter comparative trials of 1,283 acute patients
showed both symptomatic and time criterion of remission
in 32% subjects treated with aripiprazole and 22% with
haloperidol reach [8].
Aims of the study
The primary objectives of this cross-sectional study with a
6-month follow-up period were to evaluate the presence
of schizophrenia patients in remission, and to assess main-
tenance of remission status and symptomatic stability over
6 months in a population from a standard state psychiatric
outpatient service in Moscow, Russia.
The primary objective of the 1-year observational thera-
peutic study was to assess the achievement of remission
criteria in a sample of stable schizophrenia patients who
did not satisfy symptomatic criterion for remission after a
6-month period and to compare two naturalistic pharma-
cotherapeutic approaches: routine (mostly first generation
antipsychotics) and contemporary (risperidone long-act-
ing, injectable) (RLAI), recently approved as a part of the
state reimbursement program) in two comparable city dis-
trict populations of schizophrenic outpatients.
The secondary objectives of these studies were (1) to
assess the achievement of symptomatic remission in differ-
ent clinical types/courses of schizophrenia according to
the ICD-10 diagnostic manual, (2) to detect the most sig-
nificant factors associated with the achievement of remis-
sion in the sample of clinically stable patients, and (3) to
assess the prevalence of antipsychotic medications routi-
nely used in Moscow outpatient settings for the long-term




The cross-sectional study of remission rate was conducted
in two healthcare districts (first and second) of the state
psychiatric outpatient service. We included outpatients
with ICD-10 diagnoses of schizophrenia (F20.0, F20.1,
F20.2, F20.3, F20.5, F20.6) and schizoaffective disorder
(F25). Patients with diagnoses F20.8 (other schizophrenia)
and F20.9 (schizophrenia, unspecified) and other psycho-
tic, schizotypal, and delusional disorders were excluded.
The ICD-10 diagnosis was determined via the Mini-Inter-
national Neuropsychiatric Interview (MINI) [9], plus ana-
lysis of case report forms and psychiatric histories from
the patients and their families. The type of previous anti-
psychotic treatment was registered (pharmacoepidemiolo-
gical study). Nightly administration of antipsychotic drugs
at non-therapeutic dosage levels was not considered as an
antipsychotic treatment. Patients who did not meet symp-
tomatic criterion for remission were prospectively
observed over 6 months for the assessment of stability (no
change of PANSS total score > 20% and/or > 1 point for
any item of the positive subscale PANSS (P1, P2, P3, P6)
regardless of baseline rating). Patients in symptomatic
remission were observed for 6 months to assess mainte-
nance of remission status. Stable patients were stratified as
having remission and non-remission status, according to
the ICD-10 diagnosis.
In the second stage, all stable patients who did not meet
symptomatic criterion for remission were offered the
option to continue participation in a 1-year observational
study. In the first district (first group), patients were
offered the option to switch from their current antipsycho-
tic medication to long-acting injectable risperidone
(RLAI), while patients in the second district were offered
the option to participate in the observational study and
continue to receive routine naturalistic treatment (second
group).
Data in both studies were collected during routine visits
after obtaining written consent from participants (sepa-
rately for cross-sectional and observational studies).
Medications in the observational study
The medication used in the observational study was within
the state reimbursement program and was administered
by a district psychiatrist. In the first group of 42 patients,
intramuscular injections of RLAI (25, 37.5, or 50 mg) were
administered every 2 weeks. Other antipsychotics were
forbidden; only 2 or 4 mg oral risperidone was allowed for
titration or in cases of psychotic symptom exacerbation.
In the second group of 35 patients, antipsychotic
treatment was routine: 5 (14.3%) patients took a mono-
therapy of atypical antipsychotic drugs (2 oral risperi-
done, 2 clozapine, 1 quetiapine), 24 (68.6%) took a
monotherapy of typical antipsychotics (4 fluphenazine
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decanoate, 5 haloperidol decanoate, 7 haloperidol, 3 tri-
fluoperazine, 2 zuclopenthixol decanoate, 2 flupentixol
decanoate, 1 chlorpromazine), and 6 (17.1%) took com-
bined therapy (1 fluphenazine decanoate and clozapine,
1 haloperidol decanoate and chlorpromazine, 2 oral
haloperidol and chlorpromazine, 1 zuclopenthixol
decanoate and trifluoperazine, and 1 oral risperidone
and trifluoperazine).
In both groups allowable medication included anti-
parkinsonian (anticholinergic) drugs, antidepressants,
mood stabilizers, hypnotics, and benzodiazepines for
reduction of agitation.
Assessment
We defined remission according to PANSS operational
criteria [4] set up by the Remission in Schizophrenia
Working Group [3]. The symptomatic criterion includes
eight core PANSS items (delusion, unusual thought con-
tent, hallucinatory behavior, conceptual disorganization,
mannerism/posturing, blunted affect, social withdrawal,
lack of spontaneity) with a score ≤ 3. The duration criter-
ion is symptomatic remission maintenance over 6 conse-
cutive months.
In the cross-sectional study, a homogeneous cohort of
outpatients were assessed with the symptomatic criterion
of remission, the validated Russian language version of the
PANSS [10] and the Global Assessment of Functioning
(GAF) scale [1].
In the observational study, we assessed symptom sever-
ity with PANSS [10], social functioning with the Personal
and Social Performance (PSP) scale [11] and compliance
with the Rating of Medication Influences (ROMI) scale
(compliance and non-compliance subscales) [12]. All
adverse events during the study were recorded. Extrapyra-
midal side effect rates were assessed with the Simpson-
Angus scale (SAS) [13]. Body weight gain was considered
to be a 7% increase compared to baseline. In the RLAI
group, assessments of quality of life (Short-Form 36 (SF-
36) Health Survey [14]) and cognitive functions (Test for
Memory 10 words [15], Wisconsin Card Sorting Test
(WCST) [16], Trail making test (TMT) Part A and B [17],
Verbal fluency test [18]) were carried out. Assessments
occurred at baseline and 3, 6, and 12 months.
Statistical analysis
Comparison of independent variables was carried out with
the Mann-Whitney U test; comparison-dependent vari-
ables were assessed using the Wilcoxon matched-pair test
and Friedman analysis of variance (ANOVA). Spearman
rank order correlation (r values) was used as a measure of
association, including baseline patient characteristics and
achievement of remission in the 1-year observational
study. The predictive value of various factors in the
population study was assessed with logistic regression.
The general linear model (univariate) procedure was used
to perform analysis of covariance (ANCOVA) to control
for the effects of positive, negative, and general PANSS
scores (covariates) on symptomatic remission achievement
(dependent variable), with different ICD-10 diagnoses
(F20.00, F20.01, F20.02, F20.3, F20.5, F20.6) as a categori-
cal factor. Odds ratios (OR) were calculated for associa-
tions between episodic or chronic courses and
symptomatic remission in the RLAI group. Missing data
were completed with single sample averages in the cross-
sectional population study and last observation carried for-
ward (LOCF) in the 6-month follow-up and 1-year obser-
vational studies.
Ethical considerations
The treatment regime and design of the study were
approved by the local ethical committee of the Moscow
Research Institute of Psychiatry and comply with princi-
ples of the Helsinki Declaration. All included patients gave




A total of 233 outpatients in 2 psychiatric healthcare dis-
tricts had diagnoses of schizophrenia and schizoaffective
disorder (F20 and F25), but only 203 of them gave agree-
ment for participation and were thus included in the
cross-sectional study (114 in the first district and 89 in the
second district). A total of 114 (56.2%) were women. The
average age was 52.8 years (SD, 15.0), the average illness
duration 24.4 years (SD, 13.2). Most patients (144 (70.9%))
had a diagnosis of paranoid schizophrenia (F20.0); 2 (1.0%)
had hebephrenic schizophrenia (F20.1), 4 (2.0%) catatonic
schizophrenia (F20.2), 10 (4.9%) undifferentiated schizo-
phrenia (F20.3), 28 (13.8%) residual schizophrenia (F20.5),
6 (3.0%) simple schizophrenia (F20.6) and 9 (4.4%) schi-
zoaffective disorder (F25). The mean PANSS total score
was 69.2 (SD, 24.9) and the GAF score was 56.7 (SD, 11.0).
Pharmacoepidemiological data
Among the 203 outpatients included in the analysis, 126
(62%) were treated with first-generation antipsychotics
(including combined therapy), 25 (12%) with second-gen-
eration antipsychotics (including combined therapy), 14
(7%) took a combination (first-generation and second-
generation antipsychotics) and 38 (19%) did not receive
antipsychotic treatment. There were no significant differ-
ences in remission rate, total PANSS score, or GAF score
between groups of first-generation or second-generation
antipsychotics observed. However, the average age and
duration of treatment were lower in the group of patients
treated with atypical antipsychotics: mean age 35.7 years
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(SD, 9.1) and 54.6 years (SD, 10.4), respectively; duration
of treatment 8.2 years (SD, 5.9) and 24.3 years (SD, 12.5),
respectively (Mann-Whitney, P < 0.001).
Cross-sectional study with a 6-month follow-up period
The distribution of patients was as follows: 64 (31.5%) out
of 203 patients met the symptomatic criterion, whereas
139 (68.5%) did not. After the 6-month follow-up period
for assessment of symptomatic stability, 53 (82.8%) out of
64 patients maintained remission. Only 105 (75.5%) of 139
patients who did not meet the symptomatic criterion in
the cross-sectional study were stable over 6 months.
The mean GAF score was significantly higher in the
group with full remission (72.5 (SD, 7.5)) than in the stable
group that did not meet both criteria (51.8 (SD, 8.7))
(Mann-Whitney, P < 0.05).
Most patients who met full remission criteria had diag-
noses of episodic (21 (39.6%)) and remittent (8 (15.0%))
courses of paranoid schizophrenia or schizoaffective dis-
order (9 (17.0%)). The majority of patients with an episo-
dic course of disorder were classified as episodic with
progressive deficit (71.4%). In the group of stable patients
who did not meet symptomatic remission criteria, more
severe diagnoses prevailed: continuous (43 (41.0%)) and
episodic (31 (29.5%)) (primarily with stable deficit)
courses of paranoid schizophrenia, undifferentiated (6
(5.7%)) and residual (16 (15.2%)) schizophrenia, hebe-
phrenic schizophrenia (2 (1.9%)), and catatonic schizo-
phrenia (3 (2.9%)) (Table 1).
Analysis of each of the eight core remission PANSS
symptoms indicated that stable patients could be charac-
terized by a specific threshold level according to their
ICD-10 diagnosis (patients with catatonic and hebephrenic
schizophrenia were excluded because they were an unre-
presentative sample). First, the proposed threshold was
achievable for all symptoms only for those with paranoid
schizophrenia with a remittent course and schizoaffective
disorder. Second, patients with different clinical types of
schizophrenia failed to meet this level in different sympto-
matic dimensions. For example, those with paranoid schi-
zophrenia with a continuous course and undifferentiated
schizophrenia did not meet symptomatic remission for
positive and negative symptom dimensions, while those
with paranoid schizophrenia with an episodic course, resi-
dual schizophrenia, and simple schizophrenia did not
meet the negative symptom dimension. More detailed
information is shown in Table 2.
For the logistic regression, the dependent variable was
symptomatic remission, while ICD-10 diagnosis (F20.01,
F20.03, F25 vs other), age, illness duration, first-degree
relatives with psychotic disorder, disability, previous anti-
psychotic treatment and GAF score were used as indepen-
dent variables. The analysis indicated that ICD-10
diagnosis (F20.01, F20.03, F25 vs other) (OR = 5.95) and
GAF score (OR = 1.29) predicted the outcome of
symptomatic remission, whereas history of psychotic dis-
order in first-degree relatives (OR = 0.44) and presence of
disability (OR = 0.64) decreased the likelihood of sympto-
matic remission (Table 3). Age, illness duration, and pre-
vious antipsychotic treatment (atypical vs typical) variables
did not reach statistical significance.
Observational therapeutic study
Sample characteristics
In all, 77 subjects (42 patients receiving RLAI and 35
patients receiving routine treatment) were recruited to the
observational therapeutic study. At baseline, none of the
patients met the symptom severity component of the pro-
posed remission criteria, but they were stable for 6 conse-
cutive months. Most patients were women in the RLAI
(24 (57.1%)) and routine treatment (19 (54.3%)) groups.
The average age was 43.7 years (SD, 13.4) in the RLAI
group and 45.4 years (SD, 14.2) in the routine treatment
group; previous treatment duration was 16.8 years (SD,
11.7) and 15.7 years (SD, 12.3), respectively. In the RLAI
group, most patients had diagnoses of paranoid schizo-
phrenia with continuous (15 (35.7%)) and episodic
(15 (35.7%)) courses. Other diagnoses were catatonic (1
(2.4%)), undifferentiated (3 (7.1%)), residual (5 (11.9%))
and simple schizophrenia (3 (7.1%)). In the routine treat-
ment group, paranoid schizophrenia with continuous
(11 (31.4%)) and episodic (13 (37.1%)) courses also predo-
minated over other diagnoses. Other diagnoses were cata-
tonic schizophrenia (1 (2.9%)) and undifferentiated (2
(5.7%)), residual (6 (17.1%)), and simple (2 (5.7%)) schizo-
phrenia. There were no significant differences between
therapeutic groups (Table 4).
Achievement of remission
The symptomatic criterion in the RLAI group was met by
16.7% of patients at month 3, 23.8% at month 6 and 21.4%
at month 12 (Friedman ANOVA, P < 0.0001). However,
only 19% of patients met both the symptom and duration
criteria (Friedman ANOVA, P < 0.0001). In the routine
treatment group, only 5.7% of subjects achieved full remis-
sion at month 12 (Friedman ANOVA, P = 0.03). Starting
from month 3, there was a significant difference between
the groups (Mann-Whitney, P < 0.05) that continued to
months 6 and 12 (Mann-Whitney, P < 0.0001) (Figure 1).
Scores for symptom change
There was a statistically significant decrease at end point
for total PANSS score of 13.8% in the RLAI group (66.1
(SD, 10.7) and 57.0 (SD, 13.7), respectively; P < 0.0001)
and 6.8% in the routine treatment group (68.7 (SD, 12.3)
and 64.0 (SD, 13.4), respectively; P < 0.05); the difference
between the groups was also significant (Mann-Whitney,
P < 0.001). The reduction in positive PANSS score was
10.3% in the RLAI group (14.5 (SD, 4.5) and 13.0 (SD,
5.3), respectively; P < 0.05) and 7.5% in the routine treat-
ment group (16.0 (SD, 5.1) and 14.8 (SD, 5.5),
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respectively), a significant between-group effect (Mann-
Whitney, P < 0.001). The negative PANSS score reduction
was greater in the RLAI group, 10.1% (18.8 (SD, 4.3) and
16.9 (SD, 4.8), respectively; P < 0.001), as opposed to only
2.1% in the routine treatment group (19.1 (SD, 4.8) and
18.7 (SD, 5.6), respectively), a significant between-group
effect (Mann-Whitney, P < 0.05). Furthermore, there was
a significant decrease in the general PANSS score in the
RLAI group, 18.1% (33.1 (SD, 5.4) and 27.1 (SD, 7.0),
respectively; P < 0.0001), and in the routine treatment
group, 5.9% (19.1 (SD, 4.8) and 18.7 (SD, 5.6), respectively;
P < 0.05) (Mann-Whitney, P < 0.0001) (Table 5).
Functioning and compliance
A significant improvement was observed in the end point
PSP scores in the RLAI group, 15.6% (52.0 (SD, 12.3) and
60.1 (SD, 12.3), respectively; P < 0.0001), while there was a
lower increase of 4.5% in the routine treatment group
(51.3 (SD, 13.1) and 53.6 (SD, 13.5), respectively; P <
0.0001), with a significant between-group effect (Mann-
Whitney, P < 0.0001). In the patients who met remission
criteria (pooled two-group analysis) the mean PSP score
was 73.8 (SD, 12.4,) whereas it was 56.6 in patients who
did not meet the remission criteria (SD, 12.0) (Mann-
Whitney, P < 0.001).
There was no significant improvement in the ROMI
compliance subscale in either group. However, there was a
significant decrease in the non-compliance subscale score
for the RLAI group of 10.5% (17.1 (SD, 3.3) and 15.3 (SD,
3.4), respectively; P < 0.0001), compared with only 2.4%
for the routine treatment group (16.4 (SD, 4.1) and 16.0
(SD, 2.9), respectively) (Mann-Whitney, P < 0.05).
Safety
In the RLAI group, there was a 71.4% reduction in the
SAS score to end point (4.9 (SD, 6.3) and 1.4 (SD, 1.9),
respectively; P < 0.0001); in the routine treatment group
SAS score reduction was lower (13.7% (5.1 (SD, 6.1) and
4.4 (SD, 5.4), respectively)). There were ten patients with
weight gain more that 7% over the 1-year study in the
RLAI group, and three in the routine treatment group. In
the RLAI group, secondary amenorrhea occurred in nine
patients, galactorrhea in one, menorrhagia that caused dis-
continuation of the study and further hospitalization in
one, headache in two, dizziness in three and stuffiness in
the nose in two. In the routine treatment group, secondary
amenorrhea was observed in two (one patient taking oral
risperidone and one taking haloperidol decanoate and
chlorpromazine), dizziness in three (taking oral haloperi-
dol, zuclopenthixol decanoate, and oral haloperidol with
chlorpromazine), constipation in two (one taking oral
zuclopenthixol, one taking chlorpromazine), and insomnia
in one (flupentixol decanoate).
Factors associated with achievement of symptomatic
remission
A significant correlation (P < 0.05) was found between
symptomatic remission and PANSS total score (r = -0.61),
plus with positive (r = -0.57), negative (r = -0.39), and gen-
eral (r = -0.61) PANSS scores. Symptomatic remission was
associated with the results of cognitive tests: WCST (r =
-0.38), TMT Part B (r = -0.42), and PSP score (r = 0.48),
as well as with subscales of the SF-36 such as physical
functioning (r = 0.42) and social functioning (r = 0.47).
ANCOVA in the RLAI group found that ICD-10 diag-
nosis was statistically significant for achievement of symp-
tomatic remission (Figure 2). The adjusted r2 value for this
model was 0.38 (F = 4.002271, P = 0.002204). Overall,
patients with paranoid schizophrenia and progressive defi-
cit (F20.01) had a greater possibility of achieving sympto-
matic criterion of remission than patients with other
Table 1 Distribution of stable patients according to International Classification of Diseases, 10th edition (ICD-10)
diagnosis and the achievement of remission criteria (n = 158)
ICD-10 diagnosis Group of stable patients who maintained
symptomatic remission for 6 months (53 patients/
21.6% of 203)
Group of patients who were stable for 6 months, but did not
satisfy the symptomatic remission criteria (105 patients/51.7%
of 203)
Paranoid schizophrenia:











Catatonic schizophrenia 0 3 (2.9%)
Undifferentiated
schizophrenia
2 (3.8%%) 6 (5.7%)
Residual schizophrenia 9 (17.0%) 16 (15.2%)
Simple schizophrenia 2 (3.8%) 4 (3.8%)
Schizoaffective disorder 9 (17.0%) 0
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Table 2 Threshold level for each of remission criteria symptoms in a group of stable patients according to International Classification of Diseases, 10th edition
(ICD-10) diagnosis (n = 158)
Dimension of psychopathology























Psychoticism (reality distortion) Delusion 3.7 (± 1.0)/5 2.5 (± 1.1)/3 1.3 (± 0.5)/1.5 3.7 (± 0.9)/4 1.7 (± 0.9)/2 1.0 (± 0)/1 1.0 (± 0)/1
Unusual thought
content
3.8 (± 1.1)/5 2.3 (± 1.1)/3 1.5 (± 0.5)/2 3.0 (± 1.0)/4 1.7 (± 1.0)/3 1.5 (± 0.8)/2 1.2 (± 0.7)/1
Hallucinatory
behavior
3.5 (± 1.2)/4 2.0 (± 1.0)/3 1.1 (± 0.4)/1 3.7 (± 0.7)/4 1.6 (± 0.7)/2 1.0 (± 0)/1 1.0 (± 0)/1
Disorganization Conceptual
disorganization
2.2 (± 1.2)/3 1.8 (± 0.9)/3 1.1 (± 0.4)/1 2.3 (± 1.0)/3 1.9 (± 0.8)/3 1.2 (± 0.4)/1 1.1 (± 0.3)/1
Mannerisms/
posturing
2.2 (± 1.3)/3 1.9 (± 1.3)/3 1.0 (± 0)/1 1.9 (± 1.2)/3 2.0 (± 0.9)/3 1.8 (± 1.0)/3 1.0 (± 0)/1
Negative symptoms (psychomotor
poverty)
Blunted affect 3.9 (± 0.9)/4 3.2 (± 0.9)/4 1.3 (± 0.5)/1.5 3.5 (± 0.8)/4 3.2 (± 1.0)/4 4.0 (± 0.6)/4 1.6 (± 0.7)/2
Social withdrawal 4.3 (± 1.0)/5 2.9 (± 1.3)/4 1.8 (± 0.7)/2 3.2 (± 1.4)/4 3.3 (± 0.9)/4 3.8 (± 0.8)/4 1.8 (± 0.7)/2
Lack of
spontaneity
4.0 (± 1.0)/5 2.5 (± 0.9)/3 1.4 (± 0.7)/1.5 3.3 (± 1.2)/4 3.0 (± 0.8)/4 3.9 (± 0.7)/4 1.0 (± 0)/1
Values are mean, standard deviation (± SD)/75th percentile unless otherwise stated.



















diagnoses. Moreover, seven (four with F20.01, two with
F20.02, one with F20.3) of the nine patients who met
symptomatic remission criterion in the RLAI group had
an episodic course of schizophrenia, and the OR for symp-
tomatic remission was 4.0 in patients with episodic schizo-
phrenia compared with a chronic course of schizophrenia.
Discussion
The prevalence of symptomatic remission in schizophrenia
by Andreasen criteria vary widely across reported studies
(17% to 88%) [19,20]. However, for most samples in cross-
sectional studies in naturalistic settings approximately one-
third of individuals had symptomatic remission [6,21,22].
These results were confirmed in our cross-sectional study
in an outpatient schizophrenia population in one territorial
sector of Moscow city, where 31.5% of patients met the
symptomatic remission criterion. It has to be noted that
62% of patients were treated with a first-generation anti-
psychotic and only 12% with a second-generation antipsy-
chotic. In contrast, a Spanish cross-sectional study using
80.1% second-generation antipsychotics, the rate of symp-
tomatic remission was 44.8% (452 of 1,010 patients) [23].
Maintenance of remission status over a 6-month period
without changes to current antipsychotic treatment consti-
tuted 82.8% of patients, which is very close to that reported
in the previous study with the same follow-up duration
[23]. But for total outpatient population full remission cri-
teria were only fulfilled in 26.1% of cases. In a recent Ger-
man naturalistic study the remission rate over the 1-year
follow-up period was even less: 10.3% of patients [24].
The most significant factors predicting achievement of
remission reported by Lambert et al. [25], using
Table 3 Odds ratios and 95% confidence intervals of the factors significantly predicting symptomatic remission
b Odds ratio (OR) 95% Confidence interval P value
ICD-10 diagnosis (F20.01, F20.03, F25 vs other) 1.78 5.95 1.95 to 18.10 < 0.001
First degree relatives with psychotic disorder -0.85 0.44 0.18 to 0.84 < 0.05
Disability (yes or no) -1.4 0.64 0.13 to 0.49 < 0.001
GAF score 0.29 1.29 1.23 to 1.46 < 0.001
GAF = Global Assessment of Functioning; ICD-10 = International Classification of Diseases, 10th edition.
Table 4 Demographics and baseline characteristics in the 1-year observational therapeutic study
Characteristics Risperidone (long-acting, injectable) (RLAI) group Routine treatment group
Number of patients 42 35
Sex: male/female 18/24 16/19
Age (SD) 43.7 (13.4) 45.4 (14.2)
Duration of disease (SD) 16.8 (11.7) 15.7 (12.3)
Number of previous hospitalizations (SD) 4.7 (2.5) 4.2 (2.8)
Paranoid schizophrenia:
Continuous course 15/35.7% 11/31.4%
Episodic course with progressive and stable deficit 15/35.7% 13/37.1%
Remittent course 0 0
Hebephrenic schizophrenia 0 0
Catatonic schizophrenia 1/2.4% 1/2.9%
Undifferentiated schizophrenia 3/7.1% 2/5.7%
Residual schizophrenia 5/11.9% 6/17.1%
Simple schizophrenia 3/7.1% 2/5.7%
Schizoaffective disorder 0 0
PANSS total score (SD) 66.1 (10.7) 68.7 (12.3)
PANSS positive score (items 1 to 7) (SD) 14.5 (4.5) 16.0 (5.1)
PANSS negative score (items 8 to 14) (SD) 18.8 (4.3) 19.1 (4.8)
PANSS general score (items 15 to 30) (SD) 33.1 (5.4) 35.3 (6.8)
Simpson-Angus scale score (SD) 4.9 (6.3) 5.1 (6.1)
PSP score (SD) 52.0 (12.3) 51.3 (13.1)
ROMI score
Compliance subscale 14.9 (2.3) 15.4 (2.6)
Non-compliance subscale 17.1 (3.3) 16.4 (4.1)
No significant differences between groups.
PANSS = Positive and Negative Syndrome Scale; PSP = Personal and Social Performance; ROMI = Rating of Medication Influences.
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multivariate regression analysis of 12 studies, are (i)
shorter duration of untreated psychosis, (ii) better pre-
morbid adjustment, (iii) lower psychopathology or ill-
ness severity scores at baseline, (iv) better functioning
level at baseline, (v) early improvement in symptoms or
functioning, and (vi) medication adherence during treat-
ment. These predicting factors were supported by our
observational study. The most important baseline
patient characteristics associated with symptomatic
remission were symptom severity (PANSS score at base-
line), executive functions (WCST, TMT Part B), social
and personal functioning (PSP score), and quality of life
(physical functioning and social functioning subscales of
the SF-36). The relationship between symptomatic
remission and cognitive improvement was also con-
firmed by Buckley et al. [26]. Additionally, we have
observed that diagnoses of episodic (with progressive
deficit) and remittent courses of schizophrenia were asso-
ciated with an increased chance of remission as compared
to continuous and episodic courses with stable deficit.
This observation was also noted previously by Wobrock et
al. [7]. They reported that outpatients with different types
of schizophrenia by ICD-10 definition had differing
chances of achieving symptomatic remission: patients with
paranoid schizophrenia had a greater possibility of meet-
ing the international remission criteria than those with
other diagnoses, particularly residual schizophrenia.
Furthermore, each of the ICD-10 types and courses of
schizophrenia in our study differed in the threshold for
the eight core PANSS items in our sample of stable
patients. When Eberhard et al. [27] analyzed a 5-year ris-
peridone trial, they found that the core eight PANSS items
are quite common in patients with schizophrenia and
non-schizophrenic disorders with psychotic symptoms.















RLAI group Routine Treatment group










Figure 1 Remission rates at the end point (12 months) in the
risperidone (long-acting, injectable) (RLAI) and control groups
(last observation carried forward used for missing data).
Table 5 Changes of PANSS, PSP and ROMI total and subscales score over the 1-year observational therapeutic study
PANSS
score






PANSS total score (SD)
1 day 66.1 (10.7) 68.7 (12.3) -
12 month 57.0 (13.8) *** 64.0 (13.4)* < 0.01
PANSS positive score (items 1 to 7) (SD)
1 day 14.5 (4.5) 16.0 (5.1) -
12 month 13.0 (5.3)* 14.8 (5.5) < 0.01
PANSS negative score (items 8 to 14) (SD)
1 day 18.8 (4.3) 19.1 (4.8) -
12 month 16.9 (4.8)** 18.7 (5.6) < 0.05
PANSS general score (items 15 to 30) (SD)
1 day 33.1 (5.4) 35.3 (5.4) -
12 month 27.1 (7.0)*** 33.2 (6.8)* < 0.001
PSP score (SD)
1 day 52.0 (12.3) 51,3 (13.1) -
12 month 60.1 (12.3)*** 53.6 (13.5)* < 0.0001
ROMI, compliance subscale score (SD)
1 day 14.9 (2.3) 15.7 (3.0) -
12 month 15.2 (2.5) 15.5 (2.9) -
ROMI, non-compliance subscale score (SD)
1 day 17.1 (3.3) 16.4 (4.1) -
12 month 15.3 (3.4)*** 16.0 (2.9) < 0.05
Wilcoxon test (baseline vs end point): *P < 0.05; **P < 0.01; ***P < 0.001.
PANSS = Positive and Negative Syndrome Scale; PSP = Personal and Social Performance; ROMI = Rating of Medication Influences.
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(depression) and G15 (preoccupation) as potentially
important symptoms for differentiating other psychotic
disorders from schizophrenia. Therefore, our opinion is
that the symptom threshold is very strict for chronic
patients with schizophrenia and it is necessary to develop
specific remission criteria for different clinical forms and
courses of schizophrenia. This point of view agrees with
previous research performed in Russia using a categorical
approach to the psychopathology of schizophrenia and
defining remission within an interval from full recovery
(symptomatic and functional) to marked deficit with long-
term symptomatic stability of patients [28,29]. This defini-
tion is partly supported by findings in our study: 105
(75.5%) of 139 patients who did not meet the symptomatic
criterion in the cross-sectional study were stable over 6
months. Moreover, ANCOVA in the RLAI group in our
observational study showed that ICD-10 diagnosis was sta-
tistically significant for achievement of symptomatic
remission. Schizophrenia is heterogeneous in psycho-
pathology and its outcomes, and it is impossible to ignore
the different clinical types of the disorder. It is not surpris-
ing that patients with schizoaffective disorder and remit-
tent or episodic courses of paranoid schizophrenia had a
greater chance to achieve symptomatic remission. In the
observational 1-year study, stable patients switched to
RLAI had a significant reduction of psychopathological
symptoms and non-compliance rate, as well as an
improvement in social and personal functioning; however,
only 21.4% of patients met symptomatic remission criter-
ion and only 19% achieved full remission. In the routine
treatment group, the remission rate at end point was
much lower, at 5.7%. This finding agrees with some pre-
vious studies. Lasser et al. [30] found that 82 (20.8%) of
the 394 stable patients who did not meet symptomatic
remission criterion at baseline achieved it over 1 year of
treatment with RLAI. However, Rossi et al. [31] reported a
higher level of sustained remission; 32% of a sample of 347
stable patients that were switched to RLAI met remission
at week 52. Generally, patients considered to be stable
may not be at their optimal symptomatic and functional
levels, and modern therapeutic approaches can improve
their outcomes. However, the proportion of stable patients
who did not meet remission in all studies is remarkable,
and for most chronic patients the symptomatic threshold
is unachievable. This statement is also supported by results
from the medication phases of the Clinical Antipsychotic
Trials of Intervention Effectiveness (CATIE) study. Only
11.7% of patients attained symptomatic remission and
then maintained it for at least 6 months, and 55.5% experi-
enced no symptom remission at any stage [32].
There are limitations to this study. First of all, this is
one-site study, but despite this fact as patients from the
outpatient psychiatric service in two healthcare districts of
a big city were chosen randomly, we believe it can be
representative; future research in Russia is necessary how-
ever, featuring multicenter studies with sites in different
regions, including rural ones. Secondly, the sample size
was not specially estimated for the exploratory objectives,
and some analyses only included a small number of sub-
jects. Thirdly, the therapeutic study was observational in a
naturalistic setting and did not assume randomization or a
blinded design; nevertheless the clinical and demographic
characteristics of the two district populations of stable
patients were comparable. However, the psychotherapeutic
influence of switching to a completely new therapeutic
approach and additional attention from medical staff with
visits every 2 weeks for injections could be important.
Therefore, it is necessary to interpret our results cau-
tiously, and obviously further research is needed to con-
firm our findings and the importance of revising the
remission criteria according to the clinical courses and
types of schizophrenia and patient functioning level.
Conclusions
Our study demonstrates lower remission rates among out-
patients with schizophrenia and schizoaffective disorder
treated mainly with first-generation antipsychotics, and
the possibility to improve remission rate by switching to
long-acting atypical antipsychotics. However, the sympto-
matic criterion of remission suggested by the Remission in
Schizophrenia Working Group [3] was unachievable for
most stable patients in spite of the significant reduction of
their symptoms. In addition, these criteria ignore the clini-
cal course of schizophrenia and the functioning level,
which are of great importance for the remission state, so it
seems clinically relevant to develop revised remission cri-
teria that refer to the heterogeneity of this disorder and to
the variety of social outcomes.
Current effect: F(5, 32)=2,8252, p=0,03186
(Computed for covariates at their means)
Vertical bars denote 0,95 confidence intervals






































Figure 2 Symptomatic remission achievement in the
risperidone (long-acting, injectable) (RLAI) group according to
International Classification of Diseases, 10th edition (ICD-10)
diagnosis (analysis of covariance (ANCOVA)).
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